Business Context and Reporting Period
Company: Barinthus Biotherapeutics Plc.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Barinthus is a clinical-stage biopharmaceutical company focused on developing immunotherapies for autoimmune and inflammatory diseases (I&I) using its proprietary SNAP-TI platform. The company's lead candidate, VTP-1000, targets celiac disease. In January 2025, the company executed a strategic restructuring, deprioritizing its legacy infectious disease and oncology assets (including VTP-300 for Hepatitis B) to focus on I&I and extend its cash runway. In September 2025, Barinthus entered into a definitive Merger Agreement to combine with Clywedog Therapeutics, Inc. in an all-stock transaction expected to close in Q2 2026.
Key Financial Metrics
| Metric (in thousands, except per share) | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $14,969 |
| Net Loss | $(66,458) | $(61,183) |
| Net Loss Per Share (Basic & Diluted) | $(1.64) | $(1.55) |
| Research & Development Expenses | $25,564 | $42,236 |
| General & Administrative Expenses | $40,830 | $29,670 |
| Impairment of Intangible Assets | $4,667 | $0 |
| Goodwill Impairment | $0 | $12,209 |
| Cash, Cash Equivalents, and Restricted Cash | $71,852 | $112,400 |
| Accumulated Deficit | $(304,092) | $(237,664) |
| Net Cash Used in Operating Activities | $(47,979) | $(28,940) |
Material Changes vs. Prior Period
- Revenue Decline: Revenue dropped to zero in 2025 from $15.0 million in 2024. The 2024 revenue was derived from royalties related to the Vaxzevria vaccine (OUI License Agreement). AstraZeneca withdrew marketing authorization for Vaxzevria in Europe in 2024, and Barinthus terminated the OUI License Agreement in December 2025.
- Expense Reductions: Research and Development (R&D) expenses decreased by $16.7 million (39%) due to the strategic deprioritization of legacy assets (VTP-300, VTP-850, etc.) and a 65% workforce reduction. However, General and Administrative (G&A) expenses increased by $11.2 million, primarily driven by a $12.0 million swing in foreign exchange gains/losses (from a $2.4M gain in 2024 to a $9.6M loss in 2025) and increased professional fees related to the merger.
- Impairment Charges: The company recorded a $4.7 million impairment charge on intangible assets in Q3 2025 triggered by the merger agreement valuation. This contrasts with a $12.2 million goodwill impairment recorded in 2024.
- Cash Position: Cash reserves decreased by approximately $40.5 million year-over-year, primarily due to operating losses and foreign exchange impacts, though the company maintains a runway of at least 12 months.
Guidance, Outlook, and Risks
- Merger with Clywedog: The company is in the process of combining with Clywedog Therapeutics. The transaction is expected to close in Q2 2026. Upon closing, the combined entity will be renamed "Clywedog Therapeutics Holdings, Inc." and trade under the ticker "CLYD." Barinthus shareholders are expected to own approximately 34% of the combined company.
- Product Pipeline:
- VTP-1000 (Celiac Disease): Lead candidate in Phase 1 (AVALON trial). The Single Ascending Dose (SAD) portion was well-tolerated with dose-dependent effects. The Multiple Ascending Dose (MAD) portion with a gluten challenge is ongoing, with data expected in H2 2026.
- VTP-300 (Hepatitis B): Deprioritized for internal development; the company is seeking a partner to advance this asset based on positive Phase 2 data showing HBsAg reductions.
- Nasdaq Compliance: The company received a deficiency letter from Nasdaq in January 2026 regarding the minimum bid price rule (closing below $1.00 for 30 consecutive days). It has a 180-day compliance period ending June 29, 2026, to regain compliance, potentially via a reverse stock split.
- Key Risks:
- Failure to consummate the Clywedog merger.
- Need for additional capital if the merger does not close or if standalone operations require more funding than anticipated.
- Uncertainty regarding clinical trial outcomes for VTP-1000.
- Delisting risk from Nasdaq if the minimum bid price is not restored.
Investor Verification Checklist
- Merger Status: Verify the current status of the Clywedog merger, including shareholder approval timelines and regulatory clearance, as this is the primary catalyst for the company's future.
- Nasdaq Compliance: Monitor the closing bid price of ADSs (BRNS) to assess the likelihood of regaining compliance with the $1.00 minimum bid price rule by June 29, 2026.
- Cash Runway: Confirm the company's cash burn rate and whether the $71.9 million cash balance is sufficient to fund operations through the merger closing or until additional financing is secured.
- VTP-1000 Data: Await the release of data from the Multiple Ascending Dose (MAD) portion of the AVALON trial, expected in the second half of 2026, to validate the clinical potential of the lead asset.
- Foreign Exchange Exposure: Review the impact of GBP/USD fluctuations on future G&A expenses, given the significant loss recorded in 2025.